KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Common Equity (2016 - 2025)

CRISPR Therapeutics AG's Common Equity history spans 11 years, with the latest figure at $1.9 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 0.53% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, down 0.53%, while the annual FY2025 figure was $1.9 billion, 0.53% down from the prior year.
  • Common Equity for Q4 2025 was $1.9 billion at CRISPR Therapeutics AG, roughly flat from $1.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $2.6 billion in Q2 2021 and bottomed at $1.7 billion in Q2 2025.
  • The 5-year median for Common Equity is $1.9 billion (2024), against an average of $2.0 billion.
  • The largest annual shift saw Common Equity skyrocketed 185.92% in 2021 before it dropped 22.24% in 2022.
  • A 5-year view of Common Equity shows it stood at $2.4 billion in 2021, then fell by 21.84% to $1.9 billion in 2022, then rose by 0.39% to $1.9 billion in 2023, then rose by 2.62% to $1.9 billion in 2024, then dropped by 0.53% to $1.9 billion in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Common Equity are $1.9 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.7 billion (Q2 2025).